Cerevel Therapeutics Holdings Inc reports results for the quarter ended in December - Earnings Summary

Cerevel Therapeutics Holdings

22/02/2023 14:32

* Cerevel Therapeutics Holdings Inc  CERE.OQ  reported a
quarterly
adjusted loss of 59 cents​​ per share for the quarter ended in
December. The mean expectation of eleven analysts for the
quarter was for a loss of 64 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cerevel Therapeutics Holdings Inc's reported EPS for the
quarter
was a loss of 59 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Cerevel Therapeutics Holdings Inc shares had fallen
by 1.7% this
quarter.
    * The company reported a quarterly loss of $92.81 million.
    * Wall Street's median 12-month price target for Cerevel
Therapeutics Holdings Inc is $40.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
22 at 02:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.64          -0.59          Beat
 Sep. 30 2022      -0.62          -0.66          Missed
 Jun. 30 2022      -0.48          -0.62          Missed
 Mar. 31 2022      -0.42          -0.46          Missed